Co-occurring substance use and mental disorders among adults with opioid use disorder

•Co-occurring substance use and mental disorders are common among adults with OUD.•Receipt of both mental health and substance use disorder treatment is suboptimal.•Expansion of comprehensive care models for co-occurring disorders are needed. Co-occurring substance use and mental disorders among peo...

Full description

Saved in:
Bibliographic Details
Published inDrug and alcohol dependence Vol. 197; pp. 78 - 82
Main Authors Jones, Christopher M., McCance-Katz, Elinore F.
Format Journal Article
LanguageEnglish
Published Ireland Elsevier B.V 01.04.2019
Elsevier Science Ltd
Subjects
Online AccessGet full text

Cover

Loading…
Abstract •Co-occurring substance use and mental disorders are common among adults with OUD.•Receipt of both mental health and substance use disorder treatment is suboptimal.•Expansion of comprehensive care models for co-occurring disorders are needed. Co-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing these co-occurring conditions is critical for improving treatment and health outcomes. There is limited recent research on the prevalence of co-occurring disorders, demographic characteristics associated with co-occurring disorders, and receipt of mental health and substance use treatment services among those with OUD. This limits the development of targeted and resourced policies and clinical interventions. Using 2015–2017 National Survey on Drug Use and Health data, prevalence of co-occurring substance use and mental disorders and receipt of mental health and substance use treatment services was estimated for adults aged 18–64 with OUD. Multivariable logistic regression assessed demographic and substance use characteristics associated with past-year mental illness (AMI) and serious mental illness (SMI) among adults with OUD as well as treatment receipt. Among adults with OUD, prevalence of specific co-occurring substance use disorders ranged from 26.4% (95% CI:23.6%–29.4%) for alcohol to 10.6% (95% CI:8.6%–13.0%) for methamphetamine. Prevalence of AMI was 64.3% (95% CI:60.4%–67.9%) and SMI was 26.9% (95% CI:24.2%–29.8%). Receiving both mental health and substance use treatment services in the past year was reported by 24.5% (95% CI:21.5%–29.9%) of adults with OUD and AMI and 29.6% (95% CI:23.3%–36.7%) of adults with OUD and SMI. Co-occurring substance use and mental disorders are common among adults with OUD. Expanding access to comprehensive service delivery models that address the substance use and mental health co-morbidities of this population is urgently needed.
AbstractList •Co-occurring substance use and mental disorders are common among adults with OUD.•Receipt of both mental health and substance use disorder treatment is suboptimal.•Expansion of comprehensive care models for co-occurring disorders are needed. Co-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing these co-occurring conditions is critical for improving treatment and health outcomes. There is limited recent research on the prevalence of co-occurring disorders, demographic characteristics associated with co-occurring disorders, and receipt of mental health and substance use treatment services among those with OUD. This limits the development of targeted and resourced policies and clinical interventions. Using 2015–2017 National Survey on Drug Use and Health data, prevalence of co-occurring substance use and mental disorders and receipt of mental health and substance use treatment services was estimated for adults aged 18–64 with OUD. Multivariable logistic regression assessed demographic and substance use characteristics associated with past-year mental illness (AMI) and serious mental illness (SMI) among adults with OUD as well as treatment receipt. Among adults with OUD, prevalence of specific co-occurring substance use disorders ranged from 26.4% (95% CI:23.6%–29.4%) for alcohol to 10.6% (95% CI:8.6%–13.0%) for methamphetamine. Prevalence of AMI was 64.3% (95% CI:60.4%–67.9%) and SMI was 26.9% (95% CI:24.2%–29.8%). Receiving both mental health and substance use treatment services in the past year was reported by 24.5% (95% CI:21.5%–29.9%) of adults with OUD and AMI and 29.6% (95% CI:23.3%–36.7%) of adults with OUD and SMI. Co-occurring substance use and mental disorders are common among adults with OUD. Expanding access to comprehensive service delivery models that address the substance use and mental health co-morbidities of this population is urgently needed.
Background: Co-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing these co-occurring conditions is critical for improving treatment and health outcomes. There is limited recent research on the prevalence of co-occurring disorders, demographic characteristics associated with co-occurring disorders, and receipt of mental health and substance use treatment services among those with OUD. This limits the development of targeted and resourced policies and clinical interventions. Methods: Using 2015–2017 National Survey on Drug Use and Health data, prevalence of co-occurring substance use and mental disorders and receipt of mental health and substance use treatment services was estimated for adults aged 18–64 with OUD. Multivariable logistic regression assessed demographic and substance use characteristics associated with past-year mental illness (AMI) and serious mental illness (SMI) among adults with OUD as well as treatment receipt. Results: Among adults with OUD, prevalence of specific co-occurring substance use disorders ranged from 26.4% (95% CI:23.6%–29.4%) for alcohol to 10.6% (95% CI:8.6%–13.0%) for methamphetamine. Prevalence of AMI was 64.3% (95% CI:60.4%–67.9%) and SMI was 26.9% (95% CI:24.2%–29.8%). Receiving both mental health and substance use treatment services in the past year was reported by 24.5% (95% CI:21.5%–29.9%) of adults with OUD and AMI and 29.6% (95% CI:23.3%–36.7%) of adults with OUD and SMI. Conclusions: Co-occurring substance use and mental disorders are common among adults with OUD. Expanding access to comprehensive service delivery models that address the substance use and mental health co-morbidities of this population is urgently needed.
Co-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing these co-occurring conditions is critical for improving treatment and health outcomes. There is limited recent research on the prevalence of co-occurring disorders, demographic characteristics associated with co-occurring disorders, and receipt of mental health and substance use treatment services among those with OUD. This limits the development of targeted and resourced policies and clinical interventions.BACKGROUNDCo-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing these co-occurring conditions is critical for improving treatment and health outcomes. There is limited recent research on the prevalence of co-occurring disorders, demographic characteristics associated with co-occurring disorders, and receipt of mental health and substance use treatment services among those with OUD. This limits the development of targeted and resourced policies and clinical interventions.Using 2015-2017 National Survey on Drug Use and Health data, prevalence of co-occurring substance use and mental disorders and receipt of mental health and substance use treatment services was estimated for adults aged 18-64 with OUD. Multivariable logistic regression assessed demographic and substance use characteristics associated with past-year mental illness (AMI) and serious mental illness (SMI) among adults with OUD as well as treatment receipt.METHODSUsing 2015-2017 National Survey on Drug Use and Health data, prevalence of co-occurring substance use and mental disorders and receipt of mental health and substance use treatment services was estimated for adults aged 18-64 with OUD. Multivariable logistic regression assessed demographic and substance use characteristics associated with past-year mental illness (AMI) and serious mental illness (SMI) among adults with OUD as well as treatment receipt.Among adults with OUD, prevalence of specific co-occurring substance use disorders ranged from 26.4% (95% CI:23.6%-29.4%) for alcohol to 10.6% (95% CI:8.6%-13.0%) for methamphetamine. Prevalence of AMI was 64.3% (95% CI:60.4%-67.9%) and SMI was 26.9% (95% CI:24.2%-29.8%). Receiving both mental health and substance use treatment services in the past year was reported by 24.5% (95% CI:21.5%-29.9%) of adults with OUD and AMI and 29.6% (95% CI:23.3%-36.7%) of adults with OUD and SMI.RESULTSAmong adults with OUD, prevalence of specific co-occurring substance use disorders ranged from 26.4% (95% CI:23.6%-29.4%) for alcohol to 10.6% (95% CI:8.6%-13.0%) for methamphetamine. Prevalence of AMI was 64.3% (95% CI:60.4%-67.9%) and SMI was 26.9% (95% CI:24.2%-29.8%). Receiving both mental health and substance use treatment services in the past year was reported by 24.5% (95% CI:21.5%-29.9%) of adults with OUD and AMI and 29.6% (95% CI:23.3%-36.7%) of adults with OUD and SMI.Co-occurring substance use and mental disorders are common among adults with OUD. Expanding access to comprehensive service delivery models that address the substance use and mental health co-morbidities of this population is urgently needed.CONCLUSIONSCo-occurring substance use and mental disorders are common among adults with OUD. Expanding access to comprehensive service delivery models that address the substance use and mental health co-morbidities of this population is urgently needed.
Co-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing these co-occurring conditions is critical for improving treatment and health outcomes. There is limited recent research on the prevalence of co-occurring disorders, demographic characteristics associated with co-occurring disorders, and receipt of mental health and substance use treatment services among those with OUD. This limits the development of targeted and resourced policies and clinical interventions. Using 2015-2017 National Survey on Drug Use and Health data, prevalence of co-occurring substance use and mental disorders and receipt of mental health and substance use treatment services was estimated for adults aged 18-64 with OUD. Multivariable logistic regression assessed demographic and substance use characteristics associated with past-year mental illness (AMI) and serious mental illness (SMI) among adults with OUD as well as treatment receipt. Among adults with OUD, prevalence of specific co-occurring substance use disorders ranged from 26.4% (95% CI:23.6%-29.4%) for alcohol to 10.6% (95% CI:8.6%-13.0%) for methamphetamine. Prevalence of AMI was 64.3% (95% CI:60.4%-67.9%) and SMI was 26.9% (95% CI:24.2%-29.8%). Receiving both mental health and substance use treatment services in the past year was reported by 24.5% (95% CI:21.5%-29.9%) of adults with OUD and AMI and 29.6% (95% CI:23.3%-36.7%) of adults with OUD and SMI. Co-occurring substance use and mental disorders are common among adults with OUD. Expanding access to comprehensive service delivery models that address the substance use and mental health co-morbidities of this population is urgently needed.
Author McCance-Katz, Elinore F.
Jones, Christopher M.
Author_xml – sequence: 1
  givenname: Christopher M.
  surname: Jones
  fullname: Jones, Christopher M.
  email: fjr0@cdc.gov
  organization: Centers for Disease Control and Prevention, 4770 Buford Highway, Atlanta, GA 30341, USA
– sequence: 2
  givenname: Elinore F.
  surname: McCance-Katz
  fullname: McCance-Katz, Elinore F.
  organization: Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30784952$$D View this record in MEDLINE/PubMed
BookMark eNqNkU1vEzEQhi1URNPCX0CWuHDZxR8br_eCgIgCUiUu9Gy59mxx8NrBH0X997hNC1JO8cUa6ZnH43nP0EmIARDClPSUUPFu29tUb7Q3FnY9I1T2lPWEk2doReU4dYQM4gStCB9FJ0cqTtFZzlvSjpjIC3TKySiHac1W6GoTu2hMTcmFG5zrdS46GMA1A9bB4gVC0R5bl2OykDLWS2ygttWXjP-48hPHnYvOPnQ8YS_R81n7DK8e73N0dfH5x-Zrd_n9y7fNx8vODHJduoHKQVouNVAwQGbJNdOUjEQPrZhmwYZx5AyIHZloleGEw8RgttRqM8_8HL3de3cp_q6Qi1pcNuC9DhBrVqw9QNdD-2xD3xyg21hTaNMpxqhg60lI0ajXj1S9XsCqXXKLTnfqaWENkHvApJhzgvkfQom6z0Zt1f9s1H02ijLVsmmt7w9ajSu6uBhK0s4fI_i0F0Bb6a2DpLJx0NKyLoEpykZ3jOTDgcR4F5zR_hfcHaf4C2B6x0g
CitedBy_id crossref_primary_10_1111_1475_6773_14251
crossref_primary_10_1016_j_jsat_2022_108873
crossref_primary_10_1111_jmwh_13415
crossref_primary_10_1007_s11469_025_01449_7
crossref_primary_10_1080_15504263_2022_2052225
crossref_primary_10_1017_S0033291723003732
crossref_primary_10_1093_epirev_mxaa005
crossref_primary_10_1213_ANE_0000000000006280
crossref_primary_10_1016_j_ejogrb_2024_04_003
crossref_primary_10_61186_etiadpajohi_17_69_7
crossref_primary_10_1007_s11469_024_01315_y
crossref_primary_10_1007_s11606_021_07249_8
crossref_primary_10_1016_j_drugpo_2023_104159
crossref_primary_10_1016_j_drugpo_2024_104434
crossref_primary_10_1177_0706743720912860
crossref_primary_10_1177_01939459241266736
crossref_primary_10_1186_s12889_021_12104_w
crossref_primary_10_3389_fpsyt_2021_784229
crossref_primary_10_1155_2024_6299073
crossref_primary_10_1177_0310057X211066929
crossref_primary_10_1016_j_addbeh_2024_108104
crossref_primary_10_1007_s10461_020_03151_2
crossref_primary_10_1080_08897077_2020_1803179
crossref_primary_10_1111_ajad_13149
crossref_primary_10_1016_j_drugalcdep_2021_108661
crossref_primary_10_1016_j_drugalcdep_2020_108244
crossref_primary_10_1109_ACCESS_2022_3230596
crossref_primary_10_2105_AJPH_2021_306577
crossref_primary_10_1001_jamahealthforum_2023_1080
crossref_primary_10_1111_jrh_12851
crossref_primary_10_1177_11782218221103581
crossref_primary_10_1002_ejp_2114
crossref_primary_10_1080_10550887_2023_2247950
crossref_primary_10_1016_j_jsat_2021_108461
crossref_primary_10_1016_j_etdah_2024_100144
crossref_primary_10_3389_fpsyt_2022_850480
crossref_primary_10_1192_bjo_2023_81
crossref_primary_10_1080_10826084_2022_2079138
crossref_primary_10_1016_j_disamonth_2025_101853
crossref_primary_10_1016_j_drugalcdep_2023_111040
crossref_primary_10_1097_JAN_0000000000000470
crossref_primary_10_1016_j_drugalcdep_2021_109160
crossref_primary_10_1177_1357633X231190945
crossref_primary_10_54615_2231_7805_47358
crossref_primary_10_1177_09637214231162366
crossref_primary_10_1371_journal_pone_0306395
crossref_primary_10_1016_j_drugalcdep_2024_111409
crossref_primary_10_1136_bmjopen_2024_087560
crossref_primary_10_1016_j_drugalcdep_2020_108113
crossref_primary_10_1080_15332640_2023_2297392
crossref_primary_10_3928_02793695_20220510_01
crossref_primary_10_1016_j_drugalcdep_2021_108996
crossref_primary_10_1093_swr_svad015
crossref_primary_10_1177_08862605231179720
crossref_primary_10_1016_j_ygyno_2020_12_011
crossref_primary_10_1016_j_josat_2023_209023
crossref_primary_10_1111_jrh_12743
crossref_primary_10_1177_00333549231222479
crossref_primary_10_1111_adb_13282
crossref_primary_10_1186_s13722_024_00447_9
crossref_primary_10_1001_jamanetworkopen_2024_35478
crossref_primary_10_1186_s13722_023_00396_9
crossref_primary_10_1016_j_drugpo_2024_104570
crossref_primary_10_1007_s11920_022_01346_z
crossref_primary_10_1016_j_drugalcdep_2023_111051
crossref_primary_10_1093_fampra_cmab171
crossref_primary_10_1111_bcp_16055
crossref_primary_10_1016_j_pmedr_2023_102494
crossref_primary_10_1007_s12024_024_00885_6
crossref_primary_10_1186_s12920_021_01100_z
crossref_primary_10_1016_j_josat_2024_209428
crossref_primary_10_1016_j_healthpol_2023_104939
crossref_primary_10_1007_s00702_023_02720_8
crossref_primary_10_1080_24751979_2025_2473364
crossref_primary_10_1093_fampra_cmaf007
crossref_primary_10_1186_s12911_022_01869_8
crossref_primary_10_1017_S0033291721002300
crossref_primary_10_3389_fpsyg_2019_00577
crossref_primary_10_1080_07347324_2021_1972775
crossref_primary_10_1097_ADM_0000000000001140
crossref_primary_10_1080_13811118_2023_2220757
crossref_primary_10_1001_jamanetworkopen_2024_17545
crossref_primary_10_3389_fpubh_2023_1105681
crossref_primary_10_1016_j_jpsychires_2024_06_047
crossref_primary_10_1097_ADM_0000000000000961
crossref_primary_10_1016_j_drugalcdep_2021_108619
crossref_primary_10_1016_j_medleg_2023_100422
crossref_primary_10_1002_jac5_1331
crossref_primary_10_1016_j_drugpo_2023_104196
crossref_primary_10_1016_j_ypmed_2021_106817
crossref_primary_10_1080_08897077_2022_2095078
crossref_primary_10_1176_appi_prcp_20190051
crossref_primary_10_1016_j_cct_2021_106354
crossref_primary_10_1007_s44174_023_00150_4
crossref_primary_10_1016_j_cct_2024_107668
crossref_primary_10_1016_j_emc_2023_06_022
crossref_primary_10_1186_s12991_024_00517_x
crossref_primary_10_1016_j_cct_2024_107782
crossref_primary_10_14475_jhpc_2024_27_1_45
crossref_primary_10_1097_ADM_0000000000001031
crossref_primary_10_3390_children9040524
crossref_primary_10_1016_j_jsat_2021_108309
crossref_primary_10_1016_j_dadr_2023_100195
crossref_primary_10_1097_ADM_0000000000001154
crossref_primary_10_1080_10509674_2023_2182866
crossref_primary_10_1186_s12888_023_05008_z
crossref_primary_10_1111_1475_6773_13920
crossref_primary_10_2196_24561
crossref_primary_10_1016_j_ogc_2023_03_010
crossref_primary_10_1176_appi_ps_202000524
crossref_primary_10_1080_10550887_2023_2195777
crossref_primary_10_1177_1527154421989994
crossref_primary_10_1080_01612840_2020_1836540
crossref_primary_10_3389_fnsys_2022_1014768
crossref_primary_10_1186_s13722_022_00317_2
crossref_primary_10_1016_j_cct_2021_106325
crossref_primary_10_1038_s41398_021_01372_0
crossref_primary_10_30773_pi_2023_0328
crossref_primary_10_1177_26334895241301670
crossref_primary_10_1016_j_jpeds_2020_07_025
crossref_primary_10_2147_JPR_S457982
crossref_primary_10_1016_j_josat_2023_209217
crossref_primary_10_1007_s11469_022_00768_3
crossref_primary_10_1007_s10597_023_01117_x
crossref_primary_10_1080_10826084_2023_2238301
crossref_primary_10_1097_ADM_0000000000000860
crossref_primary_10_1186_s12954_023_00906_7
crossref_primary_10_3389_fpsyt_2023_1255323
crossref_primary_10_1016_j_dadr_2024_100226
crossref_primary_10_1080_15332985_2021_1928586
crossref_primary_10_1016_j_drugalcdep_2019_02_033
crossref_primary_10_1044_2022_PERSP_21_00270
crossref_primary_10_1093_jbcr_irae168
crossref_primary_10_1371_journal_pone_0292674
crossref_primary_10_1007_s10597_023_01215_w
crossref_primary_10_1176_appi_ajp_20230918
crossref_primary_10_1016_j_drugalcdep_2021_109013
crossref_primary_10_1080_14659891_2023_2293774
crossref_primary_10_1007_s40737_024_00398_z
crossref_primary_10_1016_j_drugalcdep_2022_109551
crossref_primary_10_1080_14459795_2022_2044502
crossref_primary_10_1093_epirev_mxaa011
crossref_primary_10_1111_ajad_13526
crossref_primary_10_1080_10826084_2021_1981386
crossref_primary_10_3389_fpsyt_2021_750500
crossref_primary_10_61186_etiadpajohi_17_69_245
crossref_primary_10_1176_appi_ps_202000066
crossref_primary_10_1093_epirev_mxaa009
crossref_primary_10_30770_2572_1852_109_1_29
crossref_primary_10_1111_jrh_12799
crossref_primary_10_1080_15332985_2021_1929664
crossref_primary_10_1186_s13011_023_00538_x
crossref_primary_10_1186_s12913_023_10136_z
crossref_primary_10_1371_journal_pone_0281437
crossref_primary_10_1080_15566382_2023_2201961
crossref_primary_10_1111_nyas_14209
crossref_primary_10_1186_s13722_024_00467_5
crossref_primary_10_1016_j_jogn_2024_01_004
crossref_primary_10_1111_jnu_12879
crossref_primary_10_1177_00220426211006362
crossref_primary_10_1111_add_15392
crossref_primary_10_1111_dar_13634
crossref_primary_10_1016_j_drugalcdep_2021_108811
crossref_primary_10_1186_s12913_024_11820_4
crossref_primary_10_1001_jama_2024_11913
crossref_primary_10_1016_j_dadr_2024_100287
crossref_primary_10_1071_PY22269
crossref_primary_10_1177_0844562121996222
crossref_primary_10_1016_j_jclinane_2022_110674
crossref_primary_10_1016_j_xjep_2022_100542
crossref_primary_10_1177_1178221820981998
crossref_primary_10_1016_j_jadr_2023_100695
crossref_primary_10_1001_jamanetworkopen_2021_0061
crossref_primary_10_1186_s40352_022_00201_w
crossref_primary_10_1001_jamanetworkopen_2023_15479
crossref_primary_10_1176_appi_ps_202000312
crossref_primary_10_1080_10826084_2021_1936051
crossref_primary_10_1186_s12916_024_03646_y
crossref_primary_10_1016_j_abrep_2024_100573
crossref_primary_10_1111_papr_13427
crossref_primary_10_1001_jamanetworkopen_2024_27569
crossref_primary_10_1016_j_cct_2023_107248
crossref_primary_10_1016_j_drugalcdep_2020_108083
crossref_primary_10_1111_add_15845
crossref_primary_10_1016_j_drugalcdep_2021_109232
crossref_primary_10_1080_10826084_2023_2196574
crossref_primary_10_1111_dar_13885
crossref_primary_10_1111_acem_14758
crossref_primary_10_1016_j_josat_2023_209192
crossref_primary_10_1016_j_drugalcdep_2022_109734
crossref_primary_10_1177_1073110520979383
crossref_primary_10_2196_25575
crossref_primary_10_1093_haschl_qxae165
crossref_primary_10_1016_j_drugpo_2022_103853
crossref_primary_10_1177_00220221241249461
crossref_primary_10_2196_37351
crossref_primary_10_14423_SMJ_0000000000001709
crossref_primary_10_1111_1468_0009_12470
crossref_primary_10_1111_ajad_13431
crossref_primary_10_1177_26334895231152808
crossref_primary_10_1186_s12888_022_04500_2
crossref_primary_10_3389_fpsyt_2022_881821
crossref_primary_10_1016_j_mcna_2021_08_009
crossref_primary_10_1016_j_ypmed_2019_105771
crossref_primary_10_1007_s10461_024_04325_y
crossref_primary_10_1097_ADM_0000000000000784
crossref_primary_10_7759_cureus_75629
crossref_primary_10_3390_ijerph192013481
crossref_primary_10_1016_j_drugpo_2021_103480
crossref_primary_10_1016_j_sapharm_2024_01_008
crossref_primary_10_1016_j_drugalcdep_2024_112447
crossref_primary_10_1038_s41390_021_01756_4
crossref_primary_10_1080_14659891_2023_2174908
crossref_primary_10_1016_j_ajem_2021_08_071
crossref_primary_10_1080_00952990_2024_2417820
crossref_primary_10_1016_j_drugalcdep_2023_110926
crossref_primary_10_1001_jamapsychiatry_2021_0247
crossref_primary_10_2340_17453674_2024_40708
crossref_primary_10_1007_s10943_025_02260_3
crossref_primary_10_1186_s12888_023_05436_x
crossref_primary_10_1038_s41380_020_00949_3
crossref_primary_10_1016_j_jsat_2021_108283
crossref_primary_10_1038_s41380_024_02548_y
crossref_primary_10_1016_j_abrep_2021_100382
crossref_primary_10_1002_jeab_741
crossref_primary_10_1007_s11126_022_09978_3
crossref_primary_10_1111_add_70008
crossref_primary_10_1016_j_jsat_2020_108155
crossref_primary_10_1080_10826084_2022_2064508
crossref_primary_10_1016_j_dadr_2022_100121
crossref_primary_10_1038_s44184_024_00086_7
crossref_primary_10_1111_add_15594
crossref_primary_10_1007_s11606_024_08718_6
crossref_primary_10_1007_s12671_024_02463_x
crossref_primary_10_1016_j_josat_2024_209561
crossref_primary_10_9740_mhc_2023_12_268
crossref_primary_10_1016_j_josat_2025_209681
crossref_primary_10_1080_14659891_2022_2139304
crossref_primary_10_1177_27536386231171813
crossref_primary_10_1097_JXX_0000000000000801
crossref_primary_10_1080_14656566_2020_1732349
crossref_primary_10_1016_j_drugalcdep_2020_108162
crossref_primary_10_1080_20016689_2021_1966187
crossref_primary_10_2147_SAR_S412821
crossref_primary_10_1016_j_josat_2023_209269
crossref_primary_10_1016_j_amepre_2021_04_017
crossref_primary_10_1097_ADM_0000000000001420
crossref_primary_10_1016_j_pbb_2022_173495
crossref_primary_10_1111_jrh_70009
crossref_primary_10_1016_j_josat_2023_209273
crossref_primary_10_1080_14659891_2024_2323103
crossref_primary_10_1080_21645515_2022_2123201
crossref_primary_10_1186_s12954_024_01007_9
crossref_primary_10_1016_j_jad_2023_05_080
crossref_primary_10_1097_MD_0000000000023203
crossref_primary_10_1007_s10461_023_04211_z
crossref_primary_10_1007_s10552_021_01513_2
crossref_primary_10_1016_j_ssmmh_2022_100151
crossref_primary_10_1186_s12954_023_00778_x
crossref_primary_10_1080_15332985_2021_1975014
crossref_primary_10_1080_08897077_2021_1876202
crossref_primary_10_1108_JPMH_09_2023_0076
crossref_primary_10_1089_jpm_2024_0092
crossref_primary_10_1007_s40596_020_01264_3
crossref_primary_10_1016_j_cct_2023_107294
crossref_primary_10_1097_MLR_0000000000001851
crossref_primary_10_1136_bmjopen_2020_048353
crossref_primary_10_1080_24734306_2022_2110201
crossref_primary_10_3390_ijerph22030458
crossref_primary_10_1093_haschl_qxaf003
crossref_primary_10_1097_ADM_0000000000001434
crossref_primary_10_1016_j_jsat_2021_108495
crossref_primary_10_1001_jamahealthforum_2022_1757
crossref_primary_10_1080_15504263_2021_1979349
crossref_primary_10_1016_j_drugpo_2023_104211
crossref_primary_10_1186_s13722_021_00268_0
crossref_primary_10_1108_JCRPP_09_2020_0060
crossref_primary_10_1016_j_drugalcdep_2024_111286
crossref_primary_10_2147_IJGM_S295461
crossref_primary_10_1007_s10549_020_05998_4
crossref_primary_10_1186_s13722_022_00302_9
crossref_primary_10_15585_mmwr_mm7123a1
crossref_primary_10_3390_ijerph19116474
crossref_primary_10_1080_10550887_2024_2327728
crossref_primary_10_1097_MLR_0000000000001867
crossref_primary_10_1080_10826084_2023_2247071
crossref_primary_10_1097_PAF_0000000000000888
crossref_primary_10_1097_ADM_0000000000001200
crossref_primary_10_1093_pubmed_fdaf001
crossref_primary_10_1177_0033354919863430
crossref_primary_10_1016_j_josat_2023_209054
crossref_primary_10_1148_radiol_240514
crossref_primary_10_1002_emp2_12877
crossref_primary_10_1080_00952990_2021_1887202
crossref_primary_10_1192_j_eurpsy_2024_1797
crossref_primary_10_1016_j_jad_2024_07_078
Cites_doi 10.1001/jama.2018.2844
10.1001/jama.2008.802
10.1097/ADM.0000000000000310
10.1016/j.ypmed.2018.01.019
10.1016/j.jsat.2008.06.006
10.15585/mmwr.mm6709e1
10.1007/s11606-012-2225-z
10.1300/J069v25n04_09
10.1001/jama.2011.370
ContentType Journal Article
Copyright 2019
Published by Elsevier B.V.
Copyright Elsevier Science Ltd. Apr 1, 2019
Copyright_xml – notice: 2019
– notice: Published by Elsevier B.V.
– notice: Copyright Elsevier Science Ltd. Apr 1, 2019
DBID AAYXX
CITATION
NPM
7QJ
7TK
7U3
7U7
BHHNA
C1K
K9.
NAPCQ
7X8
DOI 10.1016/j.drugalcdep.2018.12.030
DatabaseName CrossRef
PubMed
Applied Social Sciences Index & Abstracts (ASSIA)
Neurosciences Abstracts
Social Services Abstracts
Toxicology Abstracts
Sociological Abstracts
Environmental Sciences and Pollution Management
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
Nursing & Allied Health Premium
Toxicology Abstracts
Sociological Abstracts
ProQuest Health & Medical Complete (Alumni)
Social Services Abstracts
Applied Social Sciences Index and Abstracts (ASSIA)
Neurosciences Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList
Nursing & Allied Health Premium
MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Social Welfare & Social Work
EISSN 1879-0046
EndPage 82
ExternalDocumentID 30784952
10_1016_j_drugalcdep_2018_12_030
S0376871618305209
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
1B1
1P~
1RT
1~.
1~5
4.4
457
4G.
5GY
5RE
5VS
6PF
7-5
71M
8P~
9JM
9JO
AABNK
AAEDT
AAEDW
AAFJI
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AATTM
AAWTL
AAXKI
AAXLA
AAXUO
ABBQC
ABCQJ
ABFNM
ABIVO
ABJNI
ABLJU
ABMAC
ABMMH
ABMZM
ABZDS
ACDAQ
ACGFS
ACHQT
ACIEU
ACIUM
ACPRK
ACRLP
ACVFH
ADBBV
ADCNI
ADEZE
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGUBO
AGWIK
AGYEJ
AHHHB
AIEXJ
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
AOMHK
APXCP
AVARZ
AXJTR
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
IHE
J1W
KOM
M29
M39
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OGGZJ
OH0
OU-
OZT
P-8
P-9
P2P
PC.
PRBVW
Q38
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SPCBC
SSB
SSH
SSN
SSO
SSP
SSZ
T5K
TN5
WH7
Z5R
~G-
AACTN
AADPK
AAIAV
AATCM
ABLVK
ABYKQ
AFKWA
AJOXV
AKYCK
AMFUW
EFLBG
LCYCR
RIG
.GJ
29G
53G
AAQXK
AAYWO
AAYXX
ABWVN
ABXDB
ACRPL
ADMUD
ADNMO
ADVLN
AFCTW
AFJKZ
AGQPQ
AGRNS
AIGII
ASPBG
AVWKF
AZFZN
CITATION
FEDTE
FGOYB
G-2
HEG
HMK
HMO
HVGLF
HZ~
H~9
R2-
SEW
UAP
WUQ
XPP
ZGI
ZXP
ZY4
NPM
7QJ
7TK
7U3
7U7
BHHNA
C1K
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c485t-41848d38ae1ece0f83a2a1070a40f89f6247732e0d726f62c303e92efd1dacff3
IEDL.DBID .~1
ISSN 0376-8716
1879-0046
IngestDate Fri Jul 11 11:38:48 EDT 2025
Sat Jul 26 02:03:35 EDT 2025
Mon Jul 21 06:04:36 EDT 2025
Thu Apr 24 23:03:07 EDT 2025
Tue Jul 01 01:53:30 EDT 2025
Fri Feb 23 02:24:25 EST 2024
Tue Aug 26 20:29:13 EDT 2025
IsPeerReviewed true
IsScholarly true
Keywords Serious mental illness
Opioid overdose
Opioid use disorder
Co-occurring disorders
Receipt of mental health and substance use treatment
Language English
License Published by Elsevier B.V.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c485t-41848d38ae1ece0f83a2a1070a40f89f6247732e0d726f62c303e92efd1dacff3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 30784952
PQID 2216259686
PQPubID 2033333
PageCount 5
ParticipantIDs proquest_miscellaneous_2184154784
proquest_journals_2216259686
pubmed_primary_30784952
crossref_primary_10_1016_j_drugalcdep_2018_12_030
crossref_citationtrail_10_1016_j_drugalcdep_2018_12_030
elsevier_sciencedirect_doi_10_1016_j_drugalcdep_2018_12_030
elsevier_clinicalkey_doi_10_1016_j_drugalcdep_2018_12_030
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-04-01
PublicationDateYYYYMMDD 2019-04-01
PublicationDate_xml – month: 04
  year: 2019
  text: 2019-04-01
  day: 01
PublicationDecade 2010
PublicationPlace Ireland
PublicationPlace_xml – name: Ireland
– name: Lausanne
PublicationTitle Drug and alcohol dependence
PublicationTitleAlternate Drug Alcohol Depend
PublicationYear 2019
Publisher Elsevier B.V
Elsevier Science Ltd
Publisher_xml – name: Elsevier B.V
– name: Elsevier Science Ltd
References Hall, Logan, Toblin, Kaplan, Kraner, Bixler, Crosby, Paulozzi (bib0030) 2008; 300
Netherland, Botsko, Egan, Saxon, Cunningham, Finkelstein, Gourevitch, Renner, Sohler, Sullivan, Weiss, Fiellin, BHIVES Collaborative (bib0055) 2009; 36
American Psychiatric Association (bib0005) 1994
Brooklyn, Sigmon (bib0015) 2017; 11
The National Council (bib0070) 2017
Jones, McCance-Katz (bib0040) 2018
Johnson, Lanier, Merrill, Crook, Porucznik, Rolfs, Sauer (bib0035) 2013; 28
Campbell, Bahorik, VanVeldhuisen, Weisner, Rubinstein, Ray (bib0020) 2018; 110
Cunningham, Sohler, McCoy, Kunins (bib0025) 2006; 38
Substance Abuse and Mental Health Services Administration (bib0060) 2017
Jones, Einstein, Compton (bib0045) 2018; 319
Vivolo-Kantor, Seth, Gladden, Mattson, Baldwin, Kite-Powell, Coletta (bib0075) 2018; 67
Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (bib0065) 2018
Kissin, McLeod, Sonnefeld, Stanton (bib0050) 2006; 25
Bohnert, Valenstein, Bair, Ganoczy, McCarthy, Ilgen, Blow (bib0010) 2011; 305
Hall (10.1016/j.drugalcdep.2018.12.030_bib0030) 2008; 300
Jones (10.1016/j.drugalcdep.2018.12.030_bib0040) 2018
Vivolo-Kantor (10.1016/j.drugalcdep.2018.12.030_bib0075) 2018; 67
Bohnert (10.1016/j.drugalcdep.2018.12.030_bib0010) 2011; 305
Cunningham (10.1016/j.drugalcdep.2018.12.030_bib0025) 2006; 38
Johnson (10.1016/j.drugalcdep.2018.12.030_bib0035) 2013; 28
The National Council (10.1016/j.drugalcdep.2018.12.030_bib0070) 2017
Brooklyn (10.1016/j.drugalcdep.2018.12.030_bib0015) 2017; 11
Campbell (10.1016/j.drugalcdep.2018.12.030_bib0020) 2018; 110
Substance Abuse and Mental Health Services Administration (10.1016/j.drugalcdep.2018.12.030_bib0060) 2017
Kissin (10.1016/j.drugalcdep.2018.12.030_bib0050) 2006; 25
Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (10.1016/j.drugalcdep.2018.12.030_bib0065) 2018
Netherland (10.1016/j.drugalcdep.2018.12.030_bib0055) 2009; 36
American Psychiatric Association (10.1016/j.drugalcdep.2018.12.030_bib0005) 1994
Jones (10.1016/j.drugalcdep.2018.12.030_bib0045) 2018; 319
References_xml – volume: 11
  start-page: 286
  year: 2017
  end-page: 292
  ident: bib0015
  article-title: Vermont Hub-and-Spoke model of care for opioid use disorder: development, implementation, and impact
  publication-title: J. Addict. Med.
– year: 2018
  ident: bib0040
  article-title: Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder
  publication-title: Addiction
– year: 2017
  ident: bib0070
  article-title: Certified Community Behavioral Health Clinics: Fact Sheet
– volume: 36
  start-page: 244
  year: 2009
  end-page: 251
  ident: bib0055
  article-title: Factors affecting willingness to provide buprenorphine treatment
  publication-title: J. Subst. Abuse Treat.
– volume: 110
  start-page: 31
  year: 2018
  end-page: 37
  ident: bib0020
  article-title: Use of a prescription opioid registry to examine opioid misuse and overdose in an integrated health system
  publication-title: Prev. Med.
– volume: 319
  start-page: 1819
  year: 2018
  end-page: 1821
  ident: bib0045
  article-title: Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010–2016
  publication-title: JAMA
– volume: 67
  start-page: 279
  year: 2018
  end-page: 285
  ident: bib0075
  article-title: Vital signs: trends in emergency department visits for suspected opioid overdose – United States, July 2016–September 2017
  publication-title: MMWR Morb. Mortal. Wkly. Rep.
– volume: 300
  start-page: 2613
  year: 2008
  end-page: 2620
  ident: bib0030
  article-title: Patterns of abuse among unintentional pharmaceutical overdose fatalities
  publication-title: JAMA
– year: 2017
  ident: bib0060
  article-title: Results from the 2016 National Survey on Drug Use and Health
– year: 2018
  ident: bib0065
  article-title: 2017 National Survey on Drug Use and Health: Methodological Summary and Definitions
– volume: 305
  start-page: 1315
  year: 2011
  end-page: 1321
  ident: bib0010
  article-title: Association between opioid prescribing patterns and opioid overdose-related deaths
  publication-title: JAMA
– volume: 38
  start-page: 336
  year: 2006
  end-page: 340
  ident: bib0025
  article-title: Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital
  publication-title: Fam. Med.
– year: 1994
  ident: bib0005
  article-title: Diagnostic and Statistical Manual of Mental Disorders
– volume: 28
  start-page: 522
  year: 2013
  end-page: 529
  ident: bib0035
  article-title: Unintentional prescription opioid-related overdose deaths: description of decedents by next of kin or best contact, Utah, 2008–2009
  publication-title: J. Gen. Intern. Med.
– volume: 25
  start-page: 91
  year: 2006
  end-page: 103
  ident: bib0050
  article-title: Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence
  publication-title: J. Addict. Dis.
– volume: 38
  start-page: 336
  year: 2006
  ident: 10.1016/j.drugalcdep.2018.12.030_bib0025
  article-title: Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital
  publication-title: Fam. Med.
– volume: 319
  start-page: 1819
  year: 2018
  ident: 10.1016/j.drugalcdep.2018.12.030_bib0045
  article-title: Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010–2016
  publication-title: JAMA
  doi: 10.1001/jama.2018.2844
– volume: 300
  start-page: 2613
  year: 2008
  ident: 10.1016/j.drugalcdep.2018.12.030_bib0030
  article-title: Patterns of abuse among unintentional pharmaceutical overdose fatalities
  publication-title: JAMA
  doi: 10.1001/jama.2008.802
– volume: 11
  start-page: 286
  year: 2017
  ident: 10.1016/j.drugalcdep.2018.12.030_bib0015
  article-title: Vermont Hub-and-Spoke model of care for opioid use disorder: development, implementation, and impact
  publication-title: J. Addict. Med.
  doi: 10.1097/ADM.0000000000000310
– volume: 110
  start-page: 31
  year: 2018
  ident: 10.1016/j.drugalcdep.2018.12.030_bib0020
  article-title: Use of a prescription opioid registry to examine opioid misuse and overdose in an integrated health system
  publication-title: Prev. Med.
  doi: 10.1016/j.ypmed.2018.01.019
– volume: 36
  start-page: 244
  year: 2009
  ident: 10.1016/j.drugalcdep.2018.12.030_bib0055
  article-title: Factors affecting willingness to provide buprenorphine treatment
  publication-title: J. Subst. Abuse Treat.
  doi: 10.1016/j.jsat.2008.06.006
– year: 2017
  ident: 10.1016/j.drugalcdep.2018.12.030_bib0060
– year: 2018
  ident: 10.1016/j.drugalcdep.2018.12.030_bib0065
– volume: 67
  start-page: 279
  year: 2018
  ident: 10.1016/j.drugalcdep.2018.12.030_bib0075
  article-title: Vital signs: trends in emergency department visits for suspected opioid overdose – United States, July 2016–September 2017
  publication-title: MMWR Morb. Mortal. Wkly. Rep.
  doi: 10.15585/mmwr.mm6709e1
– issue: September
  year: 2018
  ident: 10.1016/j.drugalcdep.2018.12.030_bib0040
  article-title: Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder
  publication-title: Addiction
– volume: 28
  start-page: 522
  year: 2013
  ident: 10.1016/j.drugalcdep.2018.12.030_bib0035
  article-title: Unintentional prescription opioid-related overdose deaths: description of decedents by next of kin or best contact, Utah, 2008–2009
  publication-title: J. Gen. Intern. Med.
  doi: 10.1007/s11606-012-2225-z
– volume: 25
  start-page: 91
  year: 2006
  ident: 10.1016/j.drugalcdep.2018.12.030_bib0050
  article-title: Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence
  publication-title: J. Addict. Dis.
  doi: 10.1300/J069v25n04_09
– year: 2017
  ident: 10.1016/j.drugalcdep.2018.12.030_bib0070
– volume: 305
  start-page: 1315
  year: 2011
  ident: 10.1016/j.drugalcdep.2018.12.030_bib0010
  article-title: Association between opioid prescribing patterns and opioid overdose-related deaths
  publication-title: JAMA
  doi: 10.1001/jama.2011.370
– year: 1994
  ident: 10.1016/j.drugalcdep.2018.12.030_bib0005
SSID ssj0000690
Score 2.6611838
Snippet •Co-occurring substance use and mental disorders are common among adults with OUD.•Receipt of both mental health and substance use disorder treatment is...
Co-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing these...
Background: Co-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 78
SubjectTerms Adults
Alcohols
Co-occurring disorders
Comorbidity
Demographics
Demography
Drug abuse
Drug addiction
Drug use
Health information
Health status
Medical treatment
Mental disorders
Mental health
Mental health care
Mental health services
Methamphetamine
Morbidity
Mortality
Narcotics
Opioid overdose
Opioid use disorder
Opioids
Polls & surveys
Receipt of mental health and substance use treatment
Serious mental illness
Substance abuse treatment
Substance use
Substance use disorder
Title Co-occurring substance use and mental disorders among adults with opioid use disorder
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0376871618305209
https://dx.doi.org/10.1016/j.drugalcdep.2018.12.030
https://www.ncbi.nlm.nih.gov/pubmed/30784952
https://www.proquest.com/docview/2216259686
https://www.proquest.com/docview/2184154784
Volume 197
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dixMxEA_H-eKL-G21HhHEt9jdbJpk8ekoHlXxXrR4byGbD6keu6Xbvt7ffjObbFVQKPiY7AxkZyaTSTLzCyGvtZe14q5muvEFE1E5ZlWtmPQQP5fexibije7nS7lciY9X86sTshhrYTCtMvv-5NMHb517Zlmas816PftSwNzAcB-MckjmwAp2odDK396Uv3njdM4CxAypczZPyvHy2z34YecDIleWejgYxHzovy9R_wpBh6Xo4j65l2NIep6G-YCchPYhmaZCW_otXEe7DfQNHTu67c9HZLXoWOccHvi132kP7mKH-qb7PlDbepow_qnPYJw9HV4hogM8R0_xtJZ2m3W39gPHSPaYrC7ef10sWX5SgTmh5zsmYEOnfaVtKIMLRdSV5RZ2gIUV0Kij5EKpiofCKy6h5WCFCzUP0YPeXIzVE3Ladm14RmiMQWpRVbLhDmKuee2aJnoEOxSFbmQzIWqUonEZbxyfvbg2Y2LZD_NL_gblb0puQP4TUh44Nwlz4wieelSUGWtKwQsaWBiO4H134P3D9o7kno52YfL87w3nJW4spZYT8urwGWYuXsfYNnR7oAFdlAinJibkabKnw--C59WwdeXP_2toL8hdaNUp0WhKTnfbfXgJMdSuORsmyRm5c_7h0_LyFj0eHSk
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-N7gFeEIyvjjI8CfFmNXFSxxFPU8XUsa0vrGJvluOPqTAlVdP-_zvHTgEJpEp7jO2TnLP9uzv7_DPAJ2F4WTBdUlGZhOau0FQVZUG5Qf85NcpVzp_oXs_5bJF_u53cHsC0vwvj0yoj9gdM79A6loyjNser5XL8PcG14d19nJRdMscTOPTsVJMBHJ5dXM7mfwBy2GrB9tQLxISekOZl1luEYm2sJ69MRbc36FOi_22l_ueFdtbo_AU8j24kOQs9fQkHtj6CUbhrS37Ye6fWlnwmfUGz_vUKFtOGNlr7Pb_6jrSIGBs_5GTbWqJqQwLNPzGRj7Ml3UNEpGPoaInfsCXNatksTSfRN3sNi_OvN9MZja8qUJ2LyYbmGNMJkwllU6tt4kSmmMIgMFE5fpSOs7woMmYTUzCOXxqNnC2ZdQaHTjuXvYFB3dT2HRDnLBd5lvGKaXS7JqWuKmc832GeiIpXQyh6LUodKcf9yxf3ss8t-yl_6196_cuUSdT_ENKd5CrQbuwhU_YDJftrpQiEEm3DHrJfdrJ_Tb89pUf9vJARAlrJWOpjSy74EE531bh4_YmMqm2zxTY4FqlnVMuH8DbMp93vIvgKjF7Z8aO69hGezm6ur-TVxfzyPTzDmjLkHY1gsFlv7Qd0qTbVSVwyD-yxH9o
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Co-occurring+substance+use+and+mental+disorders+among+adults+with+opioid+use+disorder&rft.jtitle=Drug+and+alcohol+dependence&rft.au=Jones%2C+Christopher+M&rft.au=McCance-Katz%2C+Elinore+F&rft.date=2019-04-01&rft.pub=Elsevier+Science+Ltd&rft.issn=0376-8716&rft.eissn=1879-0046&rft.volume=197&rft.spage=78&rft_id=info:doi/10.1016%2Fj.drugalcdep.2018.12.030&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0376-8716&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0376-8716&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0376-8716&client=summon